Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression

European Journal of Endocrinology

Volumn 154, Issue 4, 2006, Pages 511-517

  Salvi, Mario ^a   Vannucchi, Guia ^a   Campi, Irene ^a   Rossi, Stefania ^c   Bonara, Paola ^b   Sbrozzi, Francesco ^a   Guastella, Claudio ^d   Avignone, Sabrina ^a   Pirola, Giacinta ^a   Ratiglia, Roberto ^a   Beck Peccoz, Paolo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Ospedale San Paolo   (Italy)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; LEVOTHYROXINE; METHYLPREDNISOLONE; PROPRANOLOL; RITUXIMAB; STEROID; THIAMAZOLE; THYROTROPIN RECEPTOR ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; B LYMPHOCYTE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DECOMPRESSION SURGERY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG RESPONSE; DRUG WITHDRAWAL; ECHOGRAPHY; ENDOCRINE OPHTHALMOPATHY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBPOPULATION; NOSE OBSTRUCTION; ORBIT; PRIORITY JOURNAL; THYROIDECTOMY;

ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; B-LYMPHOCYTES; FEMALE; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; METHYLPREDNISOLONE; MIDDLE AGED; ORBIT; RECEPTORS, THYROTROPIN; T-LYMPHOCYTES; THYROIDECTOMY; THYROTROPIN; THYROXINE;

EID: 33646025815     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02119     Document Type: Article

References (30)

1. Zakarija M & McKenzie JM. The spectrum and significance of autoantibodies reacting with the thyrotropin receptor. Endocrinology and Metabolism Clinics of North America 1987 16 343-363.
2. Costagliola S, Morgenthaler NG, Hoermann R, Badenhoop K, Struck J, Freitag D, Poertl S, Weglohner W, Hollidt JM, Quadbeck B, Dumont JE, Schumm-Draeger PM, Bergmann A, Mann K, Vassart G & Usadel KH. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. Journal of Clinical Endocrinology and Metabolism 1999 84 90-97.
3. Maugendre D & Massart C. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay. Clinical Endocrinology 2001 54 89-96.
4. Rees Smith B, McLachlan SM & Furmaniak J. Autoantibodies to the thyrotropin receptor. Endocrine Review 1988 8 106-121.
5. Michelangeli V, Poon C, Taft J, Newnham H, Topliss D & Colman P. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. Thyroid 1998 8 119-124.
6. Bahn RS. Clinical review 157: Pathophysiology of Graves' ophthalmopathy: the cycle of disease. Journal of Clinical Endocrinology and Metabolism 2003 88 1939-1946.
7. Valyasevi RW, Harteneck DA, Dutton CM & Bahn RS. Stimulation of adipogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts. Journal of Clinical Endocrinology and Metabolism 2002 87 2352-2358.
8. Cao HJ, Wang HS, Zhang Y, Lin HY, Phipps RP & Smith TJ. Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression: insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. Journal of Biological Chemistry 1998 273 29615-29625.
9. Hufnagel TJ, Hickey WF, Cobbs WH, Jakobiec FA, Iwamoto T & Eagle RC. Immunohistochemical and ultrastructural studies on the exenterated orbital tissues of a patient with Graves' disease. Ophthalmology 1984 91 1411-1419.
10. Weetman AP, Cohen S, Gatter KC, Fells P & Shine B. Immunohistochemical analysis of the retrobulbar tissues in Graves' ophthalmopathy. Clinical and Experimental Immunology 1989 75 222-227.
11. Eckstein AK, Quadbeck B, Tews S, Mann K, Kruger C, Mohr CH, Steuhl KP, Esser J & Gieseler RK. Thyroid-associated ophthalmoevidence for CD4(+) gammadelta T-cells; de novo differentiation of RFD7(+) macrophages, but not RFD1(+) dendritic cells, and loss of gammadelta and alphabeta T cell receptor expression. British Journal of Ophthalmology 2004 88 803-808.
12. Pappa A, Lawson JM, Calder V, Fells P & Lightman S. T-cells and fibroblasts in affected extraocular muscle in early and late thyroid-associated ophthalmopathy. British Journal of Ophthalmology 2000 84 517-522.
13. Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM & Prummel MF. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clinical Endocrinology 2000 52 267-271.
14. Eckstein AK, Plicht M, Lax H, Hirche H, Quadbeck B, Mann K, Steuhl KP, Esser J & Morgenthaler NG. Clinical results of antiinflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies. Clinical Endocrinology 2004 61 612-618.
15. Tsokos GC B-cells. Be Gone, B-Cell Depletion in the Treatment of Rheumatoid Arthritis. New England Journal of Medicine 2004 350 2546-2548.
16. Hasselbalch HC. B-cell depletion with rituximab - a targeted therapy for Graves' disease and autoimmune thyroiditis. Immunology Letters 2003 88 85-86.
17. Werner SC. Classification of the eye changes of Graves' disease. Journal of Clinical Endocrinology and Metabolism 1969 29 982-984.
18. Mourits MP, Prummel MF, Wiersinga WM & Koorneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clinical Endocrinology 1997 47 9-14.
19. Chiovato L, Latrofa F, Braverman LE, Pacini F, Capezzone M, Masserini L, Grasso L & Pinchera A. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Annals of Internal Medicine 2003 139 346-351.
20. El Fassi D, Nielsen CH, Hasselbalch HC & Hegedus L. Successful B lymphocyte depletion in a patient with recurrent Graves' disease and severe ophthalmopathy. Thyroid 2005 15 (Suppl 1) S28 (Abstract).
21. Male D, Cooke A, Owen M, Trowsdale J & Champion B. Antigen receptor molecules. In Advanced Immunology, Eds. D Male, A Cooke, M Owen, J Trowsdale & B Champion. pp 2.1-2.2. London: Mosby, 1996.
22. Anolik JH, Campbell D, Felgar RE, Rosenblatt J, Young F, Sanz I & Looney RJ. B lymphocyte depletion in the treatment of systemic lupus erythematosus. Arthritis and Rheumatism 2002 (Suppl 9) S717 (Abstract).
23. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM & Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. New England Journal of Medicine 2004 350 2572-2581.
24. Stasi R, Pagano A, Stipa E & Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001 98 952-957.
25. Leandro MJ, Edwards JC & Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated for B lymphocyte depletion. Annals of the Rheumatic Diseases 2002 61 883-888.
26. Segundo C, Rodriguez C, Garcia-Poley A, Aguilar M, Gavilan I, Bellas C & Brieva JA. Thyroid-infiltrating B lymphocytes in Graves' disease are related to marginal zone and memory B-cell compartments. Thyroid 2001 11 525-530.
27. Armengol MP, Juan M, Lucas-Martin A, Fernandez-Figueras MT, Jaraquemada D, Gallart T & Pujol-Borrell R. Thyroid autoimmune disease: demonstration of thyroid antigen-specific B-cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers. American Journal of Pathology 2001 159 861-873.
28. Gorman C, Leandro M & Isenberg D. B-cell depletion in autoimmune disease. Arthritis Research and Therapy 2003 5 (Suppl 4) S17-S21.
29. Takemura S, Klimiuk PA, Braun A, Coronzy JJ & Weyand CM. T cell activation in rheumatoid synovium is B-cell dependent. Journal of Immunology 2001 167 4710-4718.
30. Pritchard J, Tsui S, Horst N, Cruikshank WW & Smith TJ. Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves' disease, express high levels of IL-16 when treated with Igs against insulin-like growth factor-1 receptor. Journal of Immunology 2004 173 3564-3569.